EICHORCondition: Anemia · Anaemia · Sponsor: GlaxoSmithKline
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The study will evaluate the ability of GSK1278863 to increase the hemoglobin (Hgb) concentration, or maintain it within the target range, and the safety and efficacy of GSK1278863 over 16 weeks of treatment, in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are chronically hyporesponsive to rhEPO. The data generated will inform dose requirements for any chronic rhEPO hyporesponsive hemodialysis-dependent subjects included in future clinical trials. The study consists of a 4-week rhEPO run-in period, a 16-week GSK1278863 treatment period and a 4-week Follow-up period.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Azusa, California, United States | — |
| GSK Investigational Site | Glendale, California, United States | — |
| GSK Investigational Site | Los Angeles, California, United States | — |
| GSK Investigational Site | Simi Valley, California, United States | — |
| GSK Investigational Site | Hollywood, Florida, United States | — |
| GSK Investigational Site | St Louis, Missouri, United States | — |
| GSK Investigational Site | Amherst, New York, United States | — |
| GSK Investigational Site | Bethlehem, Pennsylvania, United States | — |
| GSK Investigational Site | Knoxville, Tennessee, United States | — |
| GSK Investigational Site | Houston, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02075463